Edit |   |
---|---|
Antigenic Specificity | CD22 (Epratuzumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1-ND |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Epratuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD22, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. |
Immunogen | n/a |
Other Names | Epratuzumab, CD22, 205923-57-5 |
Gene, Accession # | CAS: 205923-57-5 |
Catalog # | abx831008 |
Price | please inquire |
Order / More Info | CD22 (Epratuzumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950